Focused On-demand Library for tRNA (adenine(58)-N(1))-methyltransferase catalytic subunit TRMT61A

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q96FX7

UPID:

TRM61_HUMAN

Alternative names:

mRNA methyladenosine-N(1)-methyltransferase catalytic subunit TRMT61A; tRNA(m1A58)-methyltransferase subunit TRMT61A

Alternative UPACC:

Q96FX7; A6NN78; Q8N7Q9

Background:

The tRNA (adenine(58)-N(1))-methyltransferase catalytic subunit TRMT61A plays a pivotal role in the post-transcriptional modification of RNA. It is responsible for the methylation of adenine residues in tRNA and a subset of mRNAs, a process crucial for the stability and function of these molecules. Known alternatively as mRNA methyladenosine-N(1)-methyltransferase catalytic subunit TRMT61A and tRNA(m1A58)-methyltransferase subunit TRMT61A, this enzyme's activity underscores its importance in cellular translation and gene expression.

Therapeutic significance:

Understanding the role of TRMT61A could open doors to potential therapeutic strategies. Its involvement in fundamental RNA processing mechanisms positions it as a key target for interventions in diseases where these pathways are dysregulated.